An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease
Background: Respiratory syncytial virus (RSV) causes the most common type of severe lower respiratory tract infection worldwide, and the fusion (F) protein is a target for neutralizing antibodies and vaccine development. This study aimed to investigate the immunogenicity and efficacy of an mRNA-base...
Saved in:
Main Authors: | Jianglong Li, Haiyan Long, Shaoyi Chen, Zhendong Zhang, Shuang Li, Qi Liu, Jun Liu, Jiaru Cai, Liping Luo, Yucai Peng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/13/1/52 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
by: Alexander Domnich, et al.
Published: (2025-01-01) -
Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus
by: Shreya Mukhopadhyay, et al.
Published: (2025-01-01) -
The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children
by: Z Dangor, et al.
Published: (2024-11-01) -
Role of bovine respiratory syncytial virus in etiology of respiratory diseases on milk farms
by: S. V. Koteneva, et al.
Published: (2021-03-01) -
Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
by: Teresa Jackowska, et al.
Published: (2024-12-01)